Make treatment decisions with confidence for Favorable Intermediate-Risk patients

The Oncotype DX GPS assay predicts the risk of adverse pathology of favorable intermediate-risk men and can help identify lower risk patients who may be better candidates for active surveillance and detect higher-risk patients who may require immediate treatment.2,5,6

FIR adverse outcomes

Only the risk of Adverse Pathology predicts tumor biology at the time of biopsy to give you the complete picture you need to make confident decisions.2

How do you use the short-term GPS report endpoint, Adverse Pathology?

For patients with clinically low-risk prostate cancer (very low, low, or intermediate NCCN® risk) the Oncotype DX Genomic Prostate Score predicts the likelihood of favorable pathology (low-grade [3+3, 3+4], organ-confined disease). Decide whether immediate treatment is necessary or confidently opt for active surveillance.

NCCN® = National Comprehensive Cancer Network® (NCCN®)

  1. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.1.2021.
  2. Eggener et al. Urology. 2019.
  3. Reese et al. Urology. 2012.
  4. Benett et al. ASCO GU. 2021.
  5. Klein et al. Eur Urol. 2014.
  6. Cullen et al. Eur Urol. 2015.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V2.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed June 1, 2021. To view the most recent and complete version of the guideline, go online to

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. NCCN does not endorse any therapy or product.

Making cancer care smarter.™